Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03139760 · ClinicalTrials.gov registry record · NA

POWERSforID: A Telehealth Weight Management System for Adults With Intellectual Disability

A NA study, sponsored by University of Alabama at Birmingham.

Completed
Registry status
NA
Development phase
36
Enrollment target

NCT03139760: Completed NA study, sponsored by University of Alabama at Birmingham.

NCT03139760 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03139760, a NA study, has completed, sponsored by University of Alabama at Birmingham.

COMPLETED
Registry status
NA
Development phase
36 participants
Enrollment target

Study Summary

POWERSforID is a 24 week randomized control trial designed to assess the feasibility of a telehealth and coaching intervention for improving health outcomes of adults with intellectual disability. Recruitment is conducted through a disability health clinic located in Colorado Springs, CO.

Primary Outcome

Number of weekly intervention phone calls attended or missed

Interventions

  • BEHAVIORAL POWERSforID

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2016-09
Est. Completion 2018-10
Phase NA
University of Alabama at Birmingham

1,160 total trials

What the finished NCT03139760 record still lists

NCT03139760 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 1 intervention - of which POWERSforID is the first listed.

NCT03139760 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03139760 about?

NCT03139760 is a clinical study titled "POWERSforID: A Telehealth Weight Management System for Adults With Intellectual Disability". POWERSforID is a 24 week randomized control trial designed to assess the feasibility of a telehealth and coaching intervention for improving health outcomes of adults with intellectual disability. Recruitment is conducted through a disability health clinic located in Colorado Springs, CO.

What is the current status of trial NCT03139760?

This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2016-09. Estimated completion is 2018-10.

What interventions are being tested in trial NCT03139760?

The interventions under investigation include: POWERSforID (BEHAVIORAL).

Who is sponsoring clinical trial NCT03139760?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03139760's enrollment target sits among peer trials

36 1541st of 2000 higher than 437 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00929006 · 36 participants · Early Phase 1

    Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism

  • NCT01891318 · 36 participants · Phase 1

    Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study

  • NCT02291848 · 36 participants · Phase 1

    Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

  • NCT02366819 · 36 participants · Phase 4

    Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03139760, the US trial registry maintained by the National Library of Medicine. NCT03139760 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.